The Cooper Companies
COO
$68.83
+4.05%
The Cooper Companies, Inc. is a leading global eyecare company operating through two primary segments: CooperVision, a major contact lens manufacturer, and CooperSurgical, a provider of medical devices and fertility solutions. The company holds a dominant market position, controlling roughly one-fourth of the U.S. contact lens market and 17% of the U.S. IUD market, establishing itself as a key player in both vision correction and women's healthcare. The current investor narrative is focused on navigating a challenging market environment, as evidenced by a significant stock price decline and recent analyst actions, with debates likely centered on the sustainability of its growth trajectory, margin pressures, and its ability to execute in a potentially softening consumer and healthcare spending landscape.…
COO
The Cooper Companies
$68.83
Related headlines
Investment Opinion: Should I buy COO Today?
Rating & Thesis: Hold. COO presents a conflicted case where compelling valuation and improving fundamentals are overshadowed by severe technical damage and uncertain growth sustainability, warranting a neutral stance until clearer trends emerge.
Supporting Evidence: The forward P/E of 13.18x is attractive and suggests the market is pricing in significant earnings growth, anchored by analyst consensus EPS of $6.05. Q1 2026 showed a powerful operational rebound with gross margin surging to 67.88% from 56.42% the prior quarter. The company maintains a fortress balance sheet with a Debt/Equity ratio of 0.34 and generates strong TTM free cash flow of $491.2 million, providing a margin of safety. However, these positives are counterbalanced by a -20.35% six-month price decline and inconsistent sequential revenue trends.
Risks & Conditions: The two biggest risks are a reversal of the recent margin expansion and a continuation of the revenue deceleration trend. This Hold rating would upgrade to a Buy if the stock demonstrates sustained quarterly revenue growth above 5% and holds gross margins above 65% for two consecutive quarters, confirming the turnaround. It would downgrade to a Sell if the price breaks decisively below the $58.89 support level on worsening fundamentals. Relative to its own history and sector peers, the stock appears fairly valued to slightly undervalued on a forward basis, but overvalued on a trailing basis, reflecting the market's bet on a recovery.
Sign up to view all
COO 12-Month Price Forecast
COO is at an inflection point. The valuation is compelling if you believe the Q1 margin story, but the stock's momentum is deeply broken, suggesting the market does not yet believe it. The base case of stabilization and range-bound trading is most probable, given the mix of strong fundamentals and weak sentiment. The stance would upgrade to bullish on confirmation of sustained margin strength and revenue re-acceleration for two consecutive quarters. It would turn bearish if the stock breaks $58.89 support, signaling a failure of the stabilization thesis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cooper Companies's 12-month outlook, with a consensus price target around $89.48 and implied upside of +30.0% versus the current price.
Average Target
$89.48
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$55 - $89
Analyst target range
Analyst coverage for COO is limited, with only 5 analysts providing estimates, which is low for a company of its market cap and can lead to higher volatility and less efficient price discovery. The provided data includes earnings and revenue estimates but does not contain a consensus recommendation, average price target, or target price range. The estimated EPS average for the forward period is $6.05, with a narrow range from $6.005 to $6.088, indicating high conviction in near-term earnings projections among the few covering analysts. Institutional rating actions show a mix of opinions but no recent downgrades, with firms like Needham and Barclays maintaining Buy/Overweight ratings, Citigroup at Neutral, and Goldman Sachs at Sell as of late 2025 and early 2026. The lack of a defined price target range from the provided data makes it difficult to gauge the implied upside or downside from the current price. The tight range in EPS estimates suggests analysts agree on the near-term earnings power, but the wide dispersion in recommendations (from Sell to Buy) signals significant disagreement on how to value those earnings, reflecting the high uncertainty and debate surrounding the stock's investment case at its current levels.
Bulls vs Bears: COO Investment Factors
The evidence presents a classic battle between valuation and momentum. The bear case is currently stronger on a technical and sentiment basis, as evidenced by the severe underperformance and downtrend. However, the bull case is building a compelling fundamental argument centered on a dramatic margin recovery and an attractive forward P/E of 13.18x. The single most important tension in the investment debate is whether the impressive Q1 margin expansion (67.88% gross margin) is sustainable and indicative of a durable operational turnaround, or merely a temporary respite before growth concerns reassert themselves. The resolution of this tension will determine if the stock's deep discount to its historical valuation is a value trap or a buying opportunity.
Bullish
- Strong Margin Recovery in Q1: Gross margin expanded dramatically from 56.42% in Q4 2025 to 67.88% in Q1 2026, a quarter-over-quarter improvement of over 11 percentage points. This suggests effective cost control, favorable product mix, or pricing power, directly boosting profitability as operating margin also recovered to 20.78%.
- Attractive Forward Valuation: The forward P/E ratio of 13.18x is compelling, especially when compared to the elevated trailing P/E of 37.3x. This discount implies the market expects significant earnings growth, with analyst consensus pointing to forward EPS of $6.05, making the stock appear reasonably valued on future earnings.
- Robust Free Cash Flow Generation: The company generates substantial free cash flow, with TTM FCF of $491.2 million. This strong cash generation, coupled with a solid balance sheet (Debt/Equity of 0.34, Current Ratio of 1.89), provides significant financial flexibility for investments, acquisitions, or shareholder returns.
- Dominant Market Positions: COO holds a ~25% share of the U.S. contact lens market and 17% of the U.S. IUD market. These entrenched positions in defensive healthcare segments (vision correction and women's health) provide a stable revenue base and competitive moat, supporting the 6.16% YoY revenue growth in Q1.
Bearish
- Severe Price and Momentum Downtrend: The stock is down -20.35% over 6 months and -18.74% YTD, significantly underperforming the S&P 500 by over -30 percentage points on a 1-year basis. This persistent downtrend, despite a recent bounce, reflects deep negative market sentiment and a lack of confidence in near-term prospects.
- Revenue Growth Deceleration & Volatility: While Q1 revenue grew 6.16% YoY, sequential quarterly revenue has declined from $1.065B in Q3 2025 to $1.024B in Q1 2026. This inconsistency points to potential demand softness or execution challenges, raising concerns about the sustainability of top-line growth.
- Elevated Trailing P/E Despite Weak Performance: A trailing P/E of 37.3x is high, especially for a company whose stock has fallen sharply. This suggests the valuation has not fully reset to reflect the operational challenges, leaving the stock vulnerable to further multiple compression if earnings growth disappoints.
- Low Analyst Coverage & Disagreement: With only 5 covering analysts, price discovery is less efficient. Furthermore, analyst recommendations range from Sell (Goldman Sachs) to Buy (Needham, Barclays), indicating high uncertainty and a lack of consensus on the stock's fair value, which can exacerbate volatility.
COO Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -5.59% and a more severe 6-month decline of -20.35%, significantly underperforming the broader market. As of the latest data, the stock is trading near the lower end of its 52-week range, with a current price of $65.91 compared to a 52-week high of $89.83 and a low of $58.89; this positioning near the lows suggests the market is pricing in substantial negative sentiment, though it may also present a potential value opportunity if fundamentals stabilize. The stock's beta of 0.873 indicates it has been less volatile than the overall market during this decline, which is atypical for a stock in a downtrend of this magnitude and may suggest a lack of aggressive selling pressure or defensive characteristics. Recent momentum shows a mixed picture, with a 1-month price increase of 7.26% suggesting a possible near-term rebound or relief rally from deeply oversold conditions. However, this short-term strength contrasts sharply with the 3-month decline of -5.79% and the severe year-to-date drop of -18.74%, indicating the longer-term downtrend remains firmly intact. The positive 1-month relative strength of +6.52% versus the S&P 500's +0.74% is a notable divergence, but it must be sustained to signal a genuine trend reversal rather than a temporary bounce within a broader bearish structure. Key technical support is clearly defined at the 52-week low of $58.89, while major resistance sits at the 52-week high of $89.83. A decisive breakdown below the $58.89 support level would likely trigger a new leg down, while a sustained move above it could build a base for recovery. The stock's maximum drawdown of -30.05% highlights the extent of the recent decline and the significant recovery required to return to previous highs, emphasizing the high risk and potential reward at current levels given the stock's below-market volatility profile.
Beta
0.87
0.87x market volatility
Max Drawdown
-30.1%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-3.0%
Cumulative gain past year
| Period | COO Return | S&P 500 |
|---|---|---|
| 1m | +10.0% | -1.7% |
| 3m | -3.8% | +13.7% |
| 6m | -16.7% | +6.2% |
| 1y | -3.0% | +20.8% |
| ytd | -15.1% | +7.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COO Fundamental Analysis
Revenue growth has been positive but shows signs of deceleration and volatility on a quarterly basis. For Q1 2026 (ending January 2026), revenue was $1.024 billion, representing a year-over-year growth of 6.16% compared to the prior year's Q1. However, examining sequential quarters reveals inconsistency: revenue declined from $1.065 billion in Q3 2025 to $1.065 billion in Q4 2025, and then to the current $1.024 billion. Segment data for the latest period shows CooperVision driving the majority of sales at $695.1 million, while CooperSurgical contributed $329 million, indicating the contact lens business remains the core growth engine. The company is profitable, with Q1 2026 net income of $130.8 million and a net margin of 12.77%. Gross margin for the quarter was strong at 67.88%, a significant improvement from the 56.42% reported in the previous quarter (Q4 2025). This gross margin expansion from 56.42% to 67.88% quarter-over-quarter is a highly positive signal, potentially indicating better pricing, product mix, or cost control. The operating margin for Q1 2026 was 20.78%, also a substantial recovery from the 13.18% in Q4 2025, suggesting the company is effectively managing its operating expenses to preserve profitability. Balance sheet health appears solid, with a conservative debt-to-equity ratio of 0.34 and a strong current ratio of 1.89, indicating good short-term liquidity. The company generates robust free cash flow, with TTM free cash flow reported at $491.2 million, providing ample internal funding for operations and growth initiatives. Return on equity (ROE) is modest at 4.55%, and return on assets (ROA) is 2.52%, which are not particularly high but reflect a stable, asset-intensive business model. The strong free cash flow generation relative to its market cap suggests a healthy cash flow yield, supporting financial flexibility.
Quarterly Revenue
$1.0B
2026-01
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$491200000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COO Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is elevated at 37.3x, while the forward PE is significantly lower at 13.18x. This substantial gap implies the market expects a sharp recovery in earnings over the next twelve months, likely pricing in the margin improvement seen in Q1 2026 and anticipated future growth, making the stock appear much more reasonably valued on a forward-looking basis. Compared to sector averages (data not explicitly provided in the input, but typical for Medical Instruments), a trailing PE of 37.3x is likely at a premium, while a forward PE of 13.18x would be closer to or potentially below the industry average. The Price-to-Sales (PS) ratio of 3.42 and EV-to-Sales of 3.72 provide additional context, suggesting the market values each dollar of revenue at a moderate multiple. The gross margin of 60.67% and operating margin of 16.69% are healthy for the industry, which may justify a valuation premium if these levels are sustainable, but the recent volatility in margins adds uncertainty. Historically, the stock's own valuation has compressed significantly. The current trailing PE of 37.3x is below the historical high reflected in the data (e.g., 56.97 in early 2024) but above the lower end of the range seen in recent quarters. The Price-to-Book ratio of 1.70 is also below the 2.0+ levels seen for much of 2024 and early 2025. This suggests the stock is trading at a discount to its own historical valuation norms, which could indicate a value opportunity if business fundamentals stabilize, or it could reflect a permanent de-rating due to lowered growth expectations.
PE
37.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~119x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is revenue volatility, as sequential quarterly sales have declined from $1.065B to $1.024B, indicating potential demand softness in its core contact lens and fertility markets. While margins recovered strongly in Q1, the prior quarter's gross margin of 56.42% demonstrates significant susceptibility to cost pressures and mix shifts. The company's modest ROE of 4.55% suggests it may struggle to generate high returns on equity, potentially capping long-term valuation. However, these risks are mitigated by a strong balance sheet with low debt (D/E of 0.34) and robust TTM free cash flow of $491.2 million.
Market & Competitive Risks: The stock faces substantial valuation compression risk, trading at a trailing P/E of 37.3x despite its weak price action, leaving it exposed if earnings growth fails to materialize. Competitive pressures in both the contact lens and fertility markets could intensify, threatening COO's dominant market shares (~25% U.S. contact lens, 17% U.S. IUD). The stock's beta of 0.873 suggests it is less correlated to the market, but its severe underperformance (-30.6% relative strength vs. S&P 500 over 1 year) indicates company-specific and sector-related headwinds that may persist regardless of broader market direction.
Worst-Case Scenario: The worst-case scenario involves a failure to sustain Q1's margin recovery coupled with a further deceleration in revenue growth, triggering a wave of analyst downgrades. This could lead to a simultaneous compression of the forward P/E multiple and a reduction in forward EPS estimates. In this adverse scenario, the stock could re-test and break below its 52-week low of $58.89. Given the current price of $65.91, this implies a realistic downside of approximately -11% to that key support level, with further declines possible if the breakdown triggers accelerated selling.
FAQ
The key risks are, in order of severity: 1) Growth Sustainability Risk: Sequential revenue has declined for two quarters, raising doubts about demand. 2) Margin Volatility Risk: Gross margin swung from 67.88% in Q1 to 56.42% in Q4, indicating high sensitivity to costs and mix. 3) Valuation Compression Risk: The high trailing P/E of 37.3x leaves the stock vulnerable if the earnings recovery falters. 4) Sentiment & Technical Risk: The stock is in a pronounced downtrend, down -20.35% over six months, which can become a self-fulfilling prophecy.
The 12-month forecast is a wide range reflecting high uncertainty. The base case (50% probability) sees the stock trading between $65 and $75 as the company stabilizes. The bull case (30% probability), driven by sustained margin strength, targets $80 to $89. The bear case (20% probability), triggered by failed execution, could see the stock fall to $55-$60, testing the 52-week low. The most likely scenario is the base case, predicated on the assumption that the impressive Q1 margin improvement is at least partially sustainable, preventing further deep declines.
COO's valuation is bifurcated. On a trailing basis, with a P/E of 37.3x, it appears overvalued given its recent operational struggles. However, on a forward basis, the P/E of 13.18x—based on analyst EPS estimates of $6.05—suggests it is fairly valued to slightly undervalued, especially if the margin recovery holds. The market is implicitly paying a fair price for expected future earnings growth but a premium for past earnings. Compared to its own historical P/B ratio, which has fallen from over 2.0 to 1.70, the stock trades at a discount to its recent history.
COO is a speculative buy at current levels, suitable only for investors with a higher risk tolerance and a multi-quarter horizon. The forward P/E of 13.18x and strong free cash flow yield are attractive, offering a margin of safety. However, the severe -20.35% six-month decline and inconsistent revenue growth present significant near-term risk. It could be a good buy for value-oriented investors who believe the Q1 margin recovery is sustainable, but it is not a good buy for those seeking stability or momentum-driven returns.
COO is unsuitable for short-term trading due to its low beta (0.873) and broken momentum; it lacks the volatility and directional clarity traders seek. It is better suited for a long-term, patient investment horizon of 2-3 years, allowing time for the operational turnaround thesis to play out and for the stock to repair its technical damage. The lack of a dividend means total return is dependent solely on price appreciation and buybacks. Given the current inflection point, a minimum holding period of 12-18 months is suggested to properly evaluate the sustainability of the recovery.